Experience With the Use of Rituximab for the Treatment of Rheumatoid Arthritis in a Tertiary Hospital in Spain: RITAR Study.

J Clin Rheumatol · 2019 · PMC6727960 · PMID 30001257

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Nevertheless, female sex and use of rituximab in monotherapy showed a trend to lower response duration (Supplemental Digital Content 4, http://links.lww.com/RHU/A128 ).

also in 53,322 other papers

did not reach statistical significanceno p-value reported

Of interest, response duration was almost 3 months shorter in seronegative than in seropositive patients, although the differences did not reach statistical significance (Table 3 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.